As two Chinese-developed vaccines against COVID-19 enter the final stage of testing in Latin America and the Middle East, a lack of guidance on using data obtained outside China could potentially pose challenges to regulatory approvals at home.
In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.
Another important step has been taken under the Healthy China initiative, with the implementation on June 1 of a basic law on access to health care. This provides additional tailwind for a health system that appeared to efficiently contain its coronavirus outbreak and is now making further structural improvements.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.